Vaccination is the single most important control measure used in endemic countries1 91% protective efficacy demonstrated in a placebo-controlled study of Thai children (N=65,224)6 Vaccination is associated with moderate frequency of tenderness, redness, and swelling (approximately 20%)3 Mild systemic effects include fever, headache, malaise, and rash (approximately 10%)3 Persons with a history of urticaria are at increased risk for reactions Recommended primary immunization schedule 3 doses of 1.0 mL each for individuals >3 years of age given subcutaneously on days 0, 7, and 30 An abbreviated schedule of days 0, 7, and 14 can be used when the longer schedule is impractical because of time constraints A booster may be given after 2 years Safety Information Persons vaccinated with JE-VAX® should be observed for 30 minutes after vaccination and remain in areas with ready access to medical care for 10 days after vaccination. Vaccination is associated with moderate frequency of tenderness, redness, and swelling (approximately 20%). Mild systemic effects include fever, headache, malaise, and rash (approximately 10%). JE-VAX® should not be administered to anyone with hypersensitivity to proteins of rodent or neural origin, to thimerosal, or anyone with a previous adverse reaction to the vaccine (eg, urticaria and/or angioedema). As with any vaccine, vaccination with JE-VAX® may not protect 100% of susceptible individuals. Click here to view full Prescribing Information for JE-VAX®. JE-VAX® is manufactured by Biken® (Osaka, Japan) and distributed by Aventis Pasteur Inc. References: 1. World Health Organization Position Paper. Japanese encephalitis. Available at: http://www.who.int/vaccinesdiseases/diseases/je.shtml. Accessed December 10, 2001. 2. Hoke CH, Nisalak A, Sangawhipa N, et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med. 1988;319:608-614. 3. JE-VAX®, Japanese Encephalitis Virus Vaccine Inactivated, Prescribing Information, February 1997.